ישראל - עברית - Ministry of Health

novartis israel ltd - omalizumab - אבקה וממס להכנת תמיסה להזרקה - omalizumab 150 mg/dose - omalizumab - omalizumab - xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. safety and efficacy have not been established in other allergic conditions.

ישראל - עברית - Ministry of Health

sanofi israel ltd - dupilumab - תמיסה להזרקה - dupilumab 150 mg/ml - dupilumab

ישראל - עברית - Ministry of Health

sanofi israel ltd - dupilumab - תמיסה להזרקה - dupilumab 175 mg/ml - dupilumab

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - mepolizumab - אבקה להכנת תמיסה לזריקה - mepolizumab 100 mg - mepolizumab

ישראל - עברית - Ministry of Health

teva israel ltd - reslizumab - תרכיז להכנת תמיסה לאינפוזיה - reslizumab 10 mg / 1 ml - reslizumab

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - benralizumab - תמיסה להזרקה - benralizumab 30 mg / 1 ml - benralizumab

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - mepolizumab - תמיסה להזרקה - mepolizumab 100 mg / 1 ml - mepolizumab

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - tezepelumab - תמיסה להזרקה - tezepelumab 110 mg/ml - tezepelumab

ישראל - עברית - Ministry of Health

medison pharma ltd - natalizumab - תרכיז להכנת תמיסה לאינפוזיה - natalizumab 300 mg / 15 ml - natalizumab - natalizumab - tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis . to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. the safety and efficacy of tysabri beyond two years are unknown. because tysabri increases the risk of progressive multifocal leukoencephalopathy (pml), an opportunistic viral infection of the brain that usually leads to death or severe disability. tysabri is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies. safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.

ישראל - עברית - Ministry of Health

amgen europe b.v. - adalimumab - תמיסה להזרקה - adalimumab 50 mg / 1 ml - adalimumab